Prostate cancer. What’s up, Doc?
Two studies concerning the treatment of prostate cancer at intermediate risk group patients.
1) brachytherapy boost low dose to control better than the dose escalation radiation therapy in men with unfavorable-risk disease.
2) within 6 months of androgen deprivation therapy (ADT) added to radiotherapy leads to a significantly better biochemical progression-free survival and disease that radiation only about did for prostate cancer at intermediate risk.
For more information, visit